Table 2.
Crude Event Rates and Adjusted Hazard Ratios Against PCR- or LFD-Positive SARS-CoV-2 Infections, Hospitalization Within 14 Days, and Deaths Within 28 Days of a Positive PCR or LFD Test for LTCF Residents, by Prior SARS-CoV-2 Exposure and Vaccination Status
| SARS-CoV-2 Infections | ||||||
|---|---|---|---|---|---|---|
| Prior SARS-CoV-2 Exposure | Vaccination Status | Person-Days | Infections | IR/1000pd | HR (95% CI)a | HR (95% CI)a |
| Unexposed | D2 84+ d | 50 569 | 215 | 4.25 | Ref. | … |
| … | D3 0–13 d | 10 350 | 42 | 4.06 | 0.56 (0.36–0.88) | … |
| … | D3 14–48 d | 75 307 | 142 | 1.89 | 0.33 (0.24–0.46) | … |
| … | D3 49–83 d | 245 243 | 537 | 2.19 | 0.37 (0.29–0.48) | … |
| … | D3 84–111 d | 233 204 | 737 | 3.16 | 0.64 (0.51–0.80) | … |
| … | D3 112–139 d | 193 957 | 467 | 2.41 | 1.04 (0.71–1.53) | … |
| … | D3 140+ d | 142 948 | 430 | 3.01 | 1.17 (0.81–1.67) | … |
| … | D4 0+ d | 6991 | 16 | 2.29 | 0.78 (0.37–1.65) | … |
| Exposed | D2 84+ d | 16 788 | 31 | 1.85 | 0.50 (0.35–0.72) | Ref. |
| … | D3 0–13 d | 3204 | 4 | 1.25 | … | 0.30 (0.11–0.87) |
| … | D3 14–48 d | 19 271 | 12 | 0.62 | … | 0.22 (0.12–0.42) |
| … | D3 49–83 d | 63 998 | 89 | 1.39 | … | 0.45 (0.28–0.72) |
| … | D3 84–111 d | 60 728 | 112 | 1.84 | … | 0.75 (0.47–1.18) |
| … | D3 112–139 d | 50 557 | 72 | 1.42 | … | 1.34 (0.79–2.28) |
| … | D3 140+ d | 39 885 | 70 | 1.76 | … | 1.44 (0.80–2.61) |
| … | D4 0+ d | 1718 | 1 | 0.58 | … | 0.35 (0.05–2.58) |
| SARS-CoV-2 Hospitalizations | ||||||
|---|---|---|---|---|---|---|
| Prior SARS-CoV-2 Exposure | Vaccination Status | Person-Days | Hosp. | IR/1000pd | HR (95% CI)a | HR (95% CI)a |
| Unexposed | D2 84+ d | 53 453 | 15 | 0.28 | Ref. | … |
| … | D3 0–13 d | 10 629 | 2 | 0.19 | 0.31 (0.06–1.60) | … |
| … | D3 14–48 d | 77 043 | 7 | 0.09 | 0.23 (0.08–0.64) | … |
| … | D3 49–83 d | 251 213 | 21 | 0.08 | 0.18 (0.08–0.40) | … |
| … | D3 84–111 d | 243 597 | 23 | 0.09 | 0.23 (0.11–0.47) | … |
| … | D3 112–139 d | 201 821 | 13 | 0.06 | 0.30 (0.11–0.79) | … |
| … | D3 140+ d | 147 979 | 6 | 0.04 | 0.20 (0.06–0.63) | … |
| … | D4 0+ d | 7095 | 0 | 0 | — | … |
| Exposed | D2 84+ d | 17 229 | 0 | 0 | — | Ref. |
| … | D3 0–13 d | 3259 | 0 | 0 | … | — |
| … | D3 14–48 d | 19 415 | 0 | 0 | … | — |
| … | D3 49–83 d | 64 986 | 1 | 0.02 | … | — |
| … | D3 84–111 d | 62 445 | 1 | 0.02 | … | — |
| … | D3 112–139 d | 51 754 | 1 | 0.02 | … | — |
| … | D3 140+ d | 40 806 | 0 | 0 | … | — |
| … | D4 0+ d | 1720 | 0 | 0 | … | — |
| SARS-CoV-2 Mortality | ||||||
|---|---|---|---|---|---|---|
| Prior SARS-CoV-2 Exposure | Vaccination Status | Person-Days | Deaths (w. 28 d) | IR/1000pd | HR (95% CI)a | HR (95% CI)a |
| Unexposed | D2 84+ d | 55 824 | 23 | 0.41 | Ref. | … |
| … | D3 0–13 d | 10 640 | 1 | 0.09 | 0.20 (0.03–1.55) | … |
| … | D3 14–48 d | 78 127 | 6 | 0.08 | 0.17 (0.06–0.48) | … |
| … | D3 49–83 d | 254 082 | 18 | 0.07 | 0.15 (0.07–0.31) | … |
| … | D3 84–111 d | 251 293 | 27 | 0.11 | 0.15 (0.08–0.28) | … |
| … | D3 112–139 d | 210 572 | 39 | 0.19 | 0.49 (0.23–1.01) | … |
| … | D3 140+ d | 151 975 | 17 | 0.11 | 0.50 (0.20–1.27) | … |
| … | D4 0+ d | 7222 | 0 | 0 | — | … |
| Exposed | D2 84+ d | 17 565 | 0 | 0 | — | Ref. |
| … | D3 0–13 d | 3268 | 0 | 0 | … | — |
| … | D3 14–48 d | 19 506 | 1 | 0.05 | … | — |
| … | D3 49–83 d | 65 357 | 0 | 0 | … | — |
| … | D3 84–111 d | 63 674 | 9 | 0.14 | … | — |
| … | D3 112–139 d | 53 106 | 3 | 0.06 | … | — |
| … | D3 140+ d | 41 562 | 1 | 0.02 | … | — |
| … | D4 0+ d | 1720 | 0 | 0 | … | — |
Abbreviations: HR, hazard ratio; IR, incidence rate; LCTF, long-term care facility; LFD, lateral flow device; PCR, polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a
HR values in the 2 columns are from mathematically identical statistical models, but HRs in right-hand column are expressed relative to “D2 84+ d” vaccine status in individuals with prior SARS-CoV-2 infection.